Navigation Links
Cancer Doctors Across America 'Stunned' at Government's Ruling Restricting Anemia Management Protocols for Cancer Patients, Call Ruling 'Interference' in Practice of Medicine
Date:9/25/2007

Limited Coverage Under Medicare Creates Two-Tiered System of Cancer Care in America; Cancer Patients on Medicare Face Avoidable Blood Transfusions

HOUSTON, Sept. 25 /PRNewswire-USNewswire/ -- US Oncology, the nation's leading oncology network representing over 1,100 oncologists across the country, today expressed "deep concern" over a letter released yesterday by the Centers for Medicare and Medicaid Services (CMS) -- the agency which manages the nation's Medicare program. US Oncology believes that this new government policy outlined in the letter severely interferes with cancer doctors' treatment protocols, creates a two-tiered system of cancer care in America, and potentially forces many cancer patients already undergoing chemotherapy treatment to undergo avoidable blood transfusions.

"CMS has reversed over 15 years of clinical experience in the treatment of Medicare patients with ESAs without offering appropriate scientific evidence to support such a drastic change" said Dan Cohen, US Oncology Senior Vice President of Government Relations & Public Policy. "This action ignores the substantial scientific evidence submitted during the course of the CMS review, and dramatically alters the standard of care for Medicare cancer patients"

ESAs are regarded as an integral drug as part of treatment protocols in cancer patients undergoing radiation and chemotherapy. ESAs, which are an injectable biologic, increase oxygen-carrying blood in patients who are anemia deficient due to chemotherapy treatments by naturally stimulating the body to produce more red blood cells. The alternative to ESAs are blood transfusions, which more cumbersome and carry various health risks, and could measurably reduce the nation's blood supply due to this policy, according to recent estimates.

Further highlighting the issue, the U.S. Food & Drug Administration (FDA) recently found ESAs safe and effective for hemoglobin levels up to 12 grams/dcl, while CMS will now only reimburse for ESAs for beneficiaries with hemoglobin levels up to 10 grams/dcl.

The letter, issued by Dr. Barry Straube, the chief medical officer of CMS, was addressed to the American Society of Hematology, US Oncology and the American Society of Clinical Oncology, and outlined limitations on coverage of erythropoietin stimulating agents (ESAs) for cancer patients. CMS stated that they would only reconsider amending the cancer National Coverage Determination (NCD) for ESAs if evidence is submitted within 30 days to challenge the ruling.

Physicians representing US Oncology expressed "serious concern" over this ruling, following an extensive presentation of clinical evidence initially challenging the CMS decision in July, and providing detailed evidence seeking a reconsideration of the policy. US Oncology, due to its size and reporting protocols is regarded as having some of the most accurate clinical data, provided their findings in several meetings and letters to officials within CMS.

US Oncology maintains that "CMS' decision is based on misinterpretation of current scientific data, and should be immediately revised. We have provided comprehensive, science-based answers to the questions posed by CMS," said Cohen. "The new policy overlooks that evidence, and will interfere with doctors' patient protocols and clinical judgment, thereby jeopardizing patient care."

US Oncology also believes that the new policy will create "two-tiers" of cancer treatment in America. Patients with private insurance will continue to receive appropriate ESA treatment based on universal clinical protocols developed and refined over more than two decades based on a trove of clinical outcomes data.

Under the new policy, Medicare beneficiaries risk dropping to hemoglobin levels oncologists regard as inappropriately low levels, and as a result, will risk being forced to undergo blood transfusions.

"Medicare beneficiaries who are battling cancer are already fighting for their lives. They should not have to also be battling Medicare coverage policy for treatments that their personal oncologists regard as necessary," concluded Cohen.

US Oncology, headquartered in Houston, TX, is one of the nation's largest cancer treatment and research networks. US Oncology provides extensive services and support to its affiliated cancer care sites nationwide to help them expand their offering of the most advanced treatments and technologies, build integrated community-based cancer care centers, improve their therapeutic drug management programs and participate in many of the new cancer-related research studies. US Oncology is affiliated with 1,122 physicians operating in 442 locations, including 90 radiation oncology facilities in 38 states.


'/>"/>
SOURCE US Oncology
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Vitamin B12 can help in detecting cancers
6. More Accurate "PROSTATE CANCER" Test can save Unnecessary Biopsies
7. Consensus on "Combination Therapy" for Breast Cancer
8. Cancers of Colon & Rectum linked to Cigarette Smoking
9. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
10. The Cancer Rumour mill working over time
11. Want skin cancer? Please have a cigarette
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The ... beginning January 1, 2017. The name change aligns the entire company with ... improving health care quality. , “We are very proud of the achievements associated ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital Tampa ... Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies ... few hospitals and facilities have earned this distinction. This is the second time ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... (WCRI) officially opened registration today for its 33rd Annual Issues & Research ... . , The theme of the conference is “Persistent Challenges and New Opportunities: ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , a New ... Conventional Data Capture Methods for Input to Electronic Health Records: A Comparative Usability ... the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... IRIDEX Corporation (NASDAQ: IRIX ) today ... common stock, $0.01 par value (the "Offering" with such shares ... final terms of the Offering will depend on market and ... be no assurance as to whether or when the Offering ... net proceeds it will receive from this offering for working ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016 Australia ... GlobalData,s new report, "Australia Ophthalmic Lasers Market Outlook to ... Lasers market. The report provides value, in millions of ... within market segements - Excimer Lasers, Femtosecond Lasers and ... and distribution shares data for each of these market ...
(Date:12/8/2016)... , Dec. 8, 2016 Australia ... Summary GlobalData,s new report, "Australia Glaucoma Surgery ... data on the Australia Glaucoma Surgery Devices market. ... dollars, volume (in units) and average prices (USD) ... The report also provides company shares and distribution ...
Breaking Medicine Technology: